York, Pa. – September 24, 2026 – WellSpan Health has joined the SUPPORT II pivotal trial, becoming the first program in Pennsylvania to evaluate the investigational Supira System during high-risk cardiac procedures.
Loma Linda, Calif. – September 23, 2026 – Loma Linda University Medical Center becomes the first in Southern California to utilize the Supira Medical pVAD system in the SUPPORT II pivotal clinical trial.
Greenville, S.C. – August 25, 2026 – Prisma Health Heart and Vascular Institute has become the first program in the Southeastern U.S. to enroll a patient in the SUPPORT II pivotal study evaluating the Supira System.
Tulsa, Okla. – August 18, 2026 – Supira Medical has partnered with Hillcrest HealthCare System, Oklahoma Heart Institute, and Dr. Kamran Muhammad to bring the SUPPORT II pivotal study to the region, evaluating the investigational Supira System.
SACRAMENTO, Calif., June 26, 2026 – UC Davis Health has launched enrollment for the SUPPORT II Pivotal Study, evaluating the investigational Supira System. This low-profile percutaneous ventricular assist device (pVAD) is designed to provide critical, temporary hemodynamic support for high-risk patients undergoing complex coronary stenting procedures.
